A DNA Vaccine against Chikungunya Virus Is Protective in Mice and Induces Neutralizing Antibodies in Mice and Nonhuman Primates
Author Information
Author(s): Mallilankaraman Karthik, Shedlock Devon J., Bao Huihui, Kawalekar Omkar U., Fagone Paolo, Ramanathan Aarthi A., Ferraro Bernadette, Stabenow Jennifer, Vijayachari Paluru, Sundaram Senthil G., Muruganandam Nagarajan, Sarangan Gopalsamy, Srikanth Padma, Khan Amir S., Lewis Mark G., Kim J. Joseph, Sardesai Niranjan Y., Muthumani Karuppiah, Weiner David B.
Primary Institution: University of Pennsylvania School of Medicine
Hypothesis
Can a synthetic DNA vaccine effectively induce protective immunity against Chikungunya virus in mice and nonhuman primates?
Conclusion
The study demonstrates that the DNA vaccine induces strong immune responses and provides protection against Chikungunya virus in both mice and nonhuman primates.
Supporting Evidence
- Vaccination induced robust antigen-specific immune responses in mice.
- Rhesus macaques showed neutralizing antibody responses similar to those in convalescent human sera.
- The DNA vaccine construct was designed to express all three envelope proteins of the virus.
- Immunized mice showed significantly lower viremia after viral challenge.
- Histopathological evaluations indicated reduced tissue damage in vaccinated mice.
- Neutralizing antibody titers in vaccinated monkeys were comparable to those in infected humans.
- The study provides a potential model for future Chikungunya vaccine development.
- High levels of neutralizing antibodies were associated with protection against the virus.
Takeaway
Scientists created a new vaccine to protect against a virus called Chikungunya, and it worked well in mice and monkeys.
Methodology
The study involved isolating a new Chikungunya virus strain, developing a DNA vaccine, and testing its efficacy in mice and rhesus macaques.
Potential Biases
Potential conflicts of interest due to funding from commercial entities involved in vaccine development.
Limitations
The study primarily focused on animal models, and further research is needed to confirm efficacy in humans.
Participant Demographics
The study included 30 patients from outbreak areas in India, all experiencing symptoms of Chikungunya.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website